Price T Rowe Associates Inc. MD Sells 24,540 Shares of Organogenesis Holdings Inc. (NASDAQ:ORGO)

Price T Rowe Associates Inc. MD trimmed its position in shares of Organogenesis Holdings Inc. (NASDAQ:ORGO) by 45.9% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 28,899 shares of the company’s stock after selling 24,540 shares during the period. Price T Rowe Associates Inc. MD’s holdings in Organogenesis were worth $93,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Virtu Financial LLC purchased a new position in shares of Organogenesis in the 4th quarter worth $38,000. Palumbo Wealth Management LLC purchased a new position in shares of Organogenesis in the 4th quarter worth approximately $65,000. MetLife Investment Management LLC grew its position in shares of Organogenesis by 34.9% in the 4th quarter. MetLife Investment Management LLC now owns 36,593 shares of the company’s stock worth $117,000 after buying an additional 9,465 shares during the last quarter. Mariner LLC purchased a new stake in Organogenesis during the 4th quarter worth approximately $123,000. Finally, Wells Fargo & Company MN grew its position in Organogenesis by 29.6% during the 4th quarter. Wells Fargo & Company MN now owns 41,471 shares of the company’s stock worth $133,000 after purchasing an additional 9,464 shares during the last quarter. 49.57% of the stock is currently owned by institutional investors.

Organogenesis Stock Performance

ORGO opened at $3.08 on Monday. The company has a debt-to-equity ratio of 0.21, a current ratio of 3.09 and a quick ratio of 2.74. The firm has a fifty day moving average price of $4.41 and a 200 day moving average price of $3.92. Organogenesis Holdings Inc. has a 1 year low of $2.28 and a 1 year high of $6.71. The stock has a market cap of $390.71 million, a P/E ratio of -51.33 and a beta of 1.85.

Organogenesis (NASDAQ:ORGO) last posted its quarterly earnings data on Thursday, May 8th. The company reported ($0.13) earnings per share for the quarter, missing analysts’ consensus estimates of $0.04 by ($0.17). Organogenesis had a negative return on equity of 2.69% and a negative net margin of 1.62%. The company had revenue of $86.69 million for the quarter, compared to analyst estimates of $90.77 million. Equities research analysts anticipate that Organogenesis Holdings Inc. will post -0.07 earnings per share for the current year.

Insider Transactions at Organogenesis

In related news, Director Michael Joseph Driscoll sold 25,000 shares of the company’s stock in a transaction dated Tuesday, March 4th. The shares were sold at an average price of $5.10, for a total value of $127,500.00. Following the completion of the sale, the director now owns 166,879 shares of the company’s stock, valued at approximately $851,082.90. This represents a 13.03% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. Insiders own 36.90% of the company’s stock.

Analyst Ratings Changes

Separately, Morgan Stanley upped their price objective on shares of Organogenesis from $4.00 to $6.00 and gave the company an “equal weight” rating in a report on Wednesday, March 5th.

About Organogenesis

Organogenesis Holdings Inc, a regenerative medicine company, develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Novachor, a chorion membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Apligraf, a bioengineered living cell therapy that produce spectrum of cytokines and growth factors; Dermagraft, a bioengineered product that produces human collagen, ECM, proteins, cytokines, and growth factors; NuShield, dehydrated placental tissue covering amnion and chorion membranes for spongy/intermediate layer intact; and PuraPly AM, an antimicrobial barrier that enables conformability and fluid drainage.